Opko’s ModeX doses first patients in Phase 1 MDX2301 COVID-19 prevention trial

OPKO Health, Inc. +0.86% Post

OPKO Health, Inc.

OPK

1.17

1.17

+0.86%

0.00% Post
  • Opko Health unit ModeX Therapeutics dosed first participants in a Phase 1 trial of MDX2301 to prevent COVID-19.
  • No results have been presented; trial will evaluate whether MDX2301 can be given safely and tolerated across multiple administration routes.
  • MDX2301 is positioned as a first-in-class multispecific antibody intended to offer broader protection against SARS‑CoV‑2 variants than conventional monoclonal antibodies.
  • Study targets about 80 healthy volunteers plus adults at higher risk for severe COVID-19, expanding potential commercial reach beyond general prophylaxis.
  • Federal funding from HHS ASPR BARDA supports development, reducing Opko’s near-term financing burden for this program.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Opko Health Inc. published the original content used to generate this news brief on April 08, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.